Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Recruiting in Palo Alto (17 mi)

+128 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: AstraZeneca

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (metformin) throughout the study.

Research Team

Eligibility Criteria

Inclusion Criteria

Subjects with Type 2 diabetes mellitus

Treated with metformin within a defined dose range for at least 3 months prior to screening

BMI= 27-45 kg/m2

Treatment Details

Interventions

• AC2993 (Monoclonal Antibodies)
• Placebo (Other)

Participant Groups

Group I: AC2993 5 mcg (0.02 mL) Experimental Treatment 1 Intervention

Placebo, then AC2993 5 mcg, then AC2993 5 mcg

Group II: AC2993 10mcg (0.04 mL) Experimental Treatment 1 Intervention

Placebo, then AC2993 5 mcg, then AC2993 10 mcg

Group III: Placebo 0.04 mL Placebo Group 1 Intervention

Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL

Group IV: Placebo 0.02 mL Placebo Group 1 Intervention

Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Advanced Clinical Research Institute Santa Ana, CA

Valley Research Fresno, CA

DOCS at Beth Israel Medical Center Yonkers, NY

Rapid Medical Research Cleveland, OH

More Trial Locations

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials

4491

Patients Recruited

290,540,000+